GlassScriptPhysician profile
Gregory A Rosner
NPI 1346686904
$11,471.61
in general payments reported to CMS, 2019-2025
33 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,319 · 2020: $2,407 · 2021: $2,762 · 2022: $1,051 · 2023: $1,465 · 2024: $1,174 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,871 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,870.74 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,302.05 | 2019-2023 | |
| Genzyme Corporation | $1,669.90 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,361.50 | 2019-2025 | Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $824.64 | 2019-2025 | Nucala, Trelegy Ellipta |
| Alk-Abello, INC | $658.84 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $624.94 | 2019-2025 | |
| Genentech USA, INC. | $458.90 | 2019-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $411.67 | 2020-2025 | Dupixent |
| Kaleo, INC. | $395.06 | 2019-2024 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $252.03 | 2020-2024 | Hyqvia, Cuvitru |
| Optinose US, INC. | $224.63 | 2020-2025 | |
| Shire North American Group INC | $160.31 | 2019 | |
| Biocryst US Sales Co., LLC | $151.99 | 2023-2025 | Orladeyo |
| Csl Behring | $132.98 | 2024-2025 | Hizentra |
| Allergan, INC. | $124.96 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $83.76 | 2020-2022 | |
| Incyte Corporation | $66.51 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Amgen INC. | $61.06 | 2021-2025 | Tezspire |
| Neurent Medical Limited | $59.72 | 2024-2025 | Neuromark Radiofrequency Console, Neuromark Device, Neuromark System |
| Hikma Pharmaceuticals USA | $50.50 | 2024 | Ryaltris |
| Lilly USA, LLC | $45.69 | 2025 | Zepbound |
| Grifols USA, LLC | $40.51 | 2024 | Xembify |
| Ars Pharmaceuticals Operations, INC. | $37.65 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $34.89 | 2022-2023 | |
| Intersect Ent, INC. | $32.93 | 2019 | |
| Atricure, INC. | $30.41 | 2019 | |
| Blueprint Medicines Corporation | $29.76 | 2023 | Ayvakit |
| Galderma Laboratories, L.P. | $21.35 | 2025 | Nemluvio |
| Pharming Healthcare, INC. | $20.75 | 2020 | |
| Glenmark Therapeutics INC. | $14.00 | 2019 | |
| Phadia US INC. | $13.63 | 2020 | |
| Adma Biomanufacturing LLC | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Rosner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.